BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 24, 2015--
Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Amar
Sawhney, Ph.D., President, Chief Executive Officer and Chairman, will
participate in a fireside chat presentation at the Piper Jaffray 27th
Annual Healthcare Conference on Wednesday, December 2, 2015 at 9:30 a.m.
ET at The New York Palace Hotel in New York City.
A live audio webcast of the presentation can be accessed through the
Calendar of Events section of the Company's website at investors.ocutx.com.
A replay of the webcast will be available on the Company's website for
two weeks following the presentation.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
(NASDAQ: OCUL) is a biopharmaceutical company focused on the development
and commercialization of innovative therapies for diseases and
conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix's lead product candidate, DEXTENZA™, is
in Phase 3 clinical development for post-surgical ocular inflammation
and pain and allergic conjunctivitis, and in Phase 2 clinical
development for inflammatory dry eye disease. An NDA for the
post-operative ocular pain indication has been submitted to the FDA and
a third Phase 3 clinical trial is being conducted for post-operative
ocular inflammation and pain. The Company’s product candidate, OTX-TP
(sustained release travoprost) intracanalicular depot, has completed a
Phase 2b clinical trial for glaucoma and ocular hypertension. Ocular
Therapeutix is also evaluating sustained-release injectable anti-VEGF
drug depots for back-of-the-eye diseases. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal
incisions following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151124006084/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich,
212-213-0006
kminarovich@burnsmc.com
or
Media
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Sales and
Marketing
scorning@ocutx.com
